Dyne Therapeutics Stock (NASDAQ:DYN)

Forecast Revenue Ownership Financials Chart

Previous Close

$19.69

52W Range

$6.36 - $27.59

50D Avg

$18.74

200D Avg

$13.21

Market Cap

$2.77B

Avg Vol (3M)

$2.94M

Beta

1.30

Div Yield

DYN Company Profile

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

192

IPO Date

Sep 17, 2020

Website

DYN Performance

DYN Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-343.89M	$-242.16M	$-170.96M
Net Income	$-317.42M	$-235.94M	$-165.24M
EBITDA	$-343.89M	$-233.48M	$-164.75M
Basic EPS	$-3.37	$-3.95	$-3.18
Diluted EPS	$-3.37	$-3.95	$-3.18

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 17Aug 04, 17 | 5:00 PM

Q1 17May 06, 17 | 5:00 PM

Q4 16Feb 24, 17 | 5:00 PM

Peer Comparison

Ticker	Company
TLX	Telix Pharmaceuticals Limited
AAPG	ASCENTAGE PHARMA GROUP INTERNATIONAL
MIRM	Mirum Pharmaceuticals, Inc.
RARE	Ultragenyx Pharmaceutical Inc.
SLNO	Soleno Therapeutics, Inc.
CELC	Celcuity Inc.
CGON	CG Oncology, Inc. Common stock
XENE	Xenon Pharmaceuticals Inc.
CNTA	Centessa Pharmaceuticals plc
APGE	Apogee Therapeutics, Inc.